Jan 5 |
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
|
Jan 5 |
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
|
Dec 19 |
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
|
Dec 13 |
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says
|
Dec 4 |
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
|
Nov 30 |
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
|